T-cell Subpopulation in Patients with Metastatic Renal Cell Carcinoma Treated by Recombinant Interleukin-2, Recombinant Interferon-α, 5-Fluorouracil, and Vinblastine

1999 ◽  
Vol 17 (4) ◽  
pp. 259-263 ◽  
Author(s):  
Eliahu Gez ◽  
Tamar Mekori ◽  
Lily Struminger ◽  
Rafael Rubinov ◽  
Ofer Nativ ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
T Cell ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Cell Subpopulation ◽  
Interferon Α ◽  
Recombinant Interferon ◽  
Recombinant Interleukin 2

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.

1995 ◽  
Vol 13 (2) ◽  
pp. 497-501 ◽  
Author(s):  
J Atzpodien ◽  
E Lopez Hänninen ◽  
H Kirchner ◽  
H Bodenstein ◽  
M Pfreundschuh ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Interferon Alfa ◽  
World Health ◽  
Home Therapy ◽  
Who Grade ◽  
Recombinant Interferon

PURPOSE In a phase II multiinstitutional outpatient trial, patients with progressive metastatic renal cell carcinoma were treated with a combination of subcutaneous (SC) recombinant interleukin-2 (rIL-2) and recombinant interferon alfa-2 (rIFN alpha 2). PATIENTS AND METHODS One hundred fifty-two patients with metastatic renal cell carcinoma were treated. Treatment courses consisted of SC rIL-2 at 20 x 10(6) IU/m2 three times per week in weeks 1 and 4, and at 5 x 10(6) IU/m2 three times per week in weeks 2, 3, 5, and 6. Additionally, patients received SC rIFN alpha 2 6 x 10(6) U/m2 once per week in weeks 1 and 4, and three times per week in weeks 2, 3, 5, and 6. RESULTS There were nine (6%) complete responses (CRs) and 29 (19%) partial responses (PRs), for an overall response rate of 25% (95% confidence interval, 19% to 32%). The median duration of responses for CRs and PRs was 16+ and 9 months, respectively. Additionally, 55 patients (36%) had stable disease (SD). Fifty-nine patients (39%) had continued disease progression (PD) despite treatment, or went off study after less than 4 weeks of therapy. The majority of patients treated experienced fever, chills, malaise, nausea, vomiting, and anorexia, side effects that were mostly limited to World Health Organization (WHO) grade 1 and 2. However, one patient developed grade 4 CNS toxicity with extended somnolence. On cessation of therapy, the neurologic symptoms in this patient were fully reversible, with no neurologic deficiency. CONCLUSION In summary, this multiinstitutional home-therapy setting of SC rIL-2 and SC rIFN alpha 2 in patients with progressive metastatic renal cell carcinoma demonstrated drastically reduced systemic toxicity, while it confirmed the therapeutic efficacy of the low-dose SC immunotherapy combination schedule.

scholarly journals Subcutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon α

Cancer ◽  
2002 ◽  
Vol 95 (11) ◽  
pp. 2324-2330 ◽  
Author(s):  
Alain Ravaud ◽  
Rémy Delva ◽  
Fréderic Gomez ◽  
Christine Chevreau ◽  
Jean-Yves Douillard ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Interferon Α

scholarly journals Recombinant interleukin 2 for metastatic renal cell carcinoma in haemodialysis patients

1992 ◽  
Vol 28 (10) ◽  
pp. 1770-1771 ◽  
Author(s):  
J. Buter ◽  
R.A.J. Janssen ◽  
N.H. Mulder ◽  
P.E. de Jong ◽  
L. de Leij ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Recombinant Interleukin 2
Sign in / Sign up

Export Citation Format

Share Document